Cleveland Diagnostics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2013

Location

Cleveland OH US

Primary Industry

Biotechnology

About

Founded in 2013 and based in Ohio, US, Cleveland Diagnostics, Inc. offers testing solutions for early detection of cancer and other high-grade disease. As of 2024, the company is headed by its CEO Arnon Chait. In January 2024, the firm raised USD 56.5 million in growth capital funding led by investor Novo Holdings, with participation from another investor Symbiotic Capital. Other investors also participated in the round. The product of Cleveland Diagnostics is the IsoPSA® test. This test is designed to offer a precise assessment of prostate cancer risk compared to traditional PSA tests. The test provides insights into the presence of aggressive cancer, thereby improving patient management and treatment decisions. The company plans to use the January 2024 funding to accelerate its commercial and corporate development programs, including its early-detection oncology testing platform.

Current Investors

LYFE Capital, Cleveland Clinic Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biotechnology, Diagnostic, Medical & Imaging Laboratories

Website

www.clevelanddx.com

Verticals

HealthTech

Company Stage

Series E

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.